Mary Dooley
Vermögen: 8 666 $ am 31.05.2026
Vermögen: 8 666 $ am 31.05.2026
Mary Beth Dooley is currently Chief Executive & Financial Officer at Synlogic, Inc., a position starting in 2025.
Formerly, Ms. Dooley was Senior Manager-Financial Planning Analysis at Idera Pharmaceuticals, Inc. from 2014 to 2018 and Assistant Vice President at Boston Private Bank & Trust Co. from 2005 to 2011.
Education includes undergraduate studies at Bates College and graduate studies including an MBA at Northeastern University.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
SYNLOGIC INC 0,11 % | 31.03.2026 | 12.744 ( 0,11 % ) | 8 666 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| SYNLOGIC, INC. | Vorstandsvorsitzender | 01.01.2025 |
| Unternehmen | Position | Ende |
|---|---|---|
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops drug candidates for oncology and rare disease indications | Corporate Officer/Principal | 01.05.2018 |
Boston Private Bank & Trust Co.
Boston Private Bank & Trust Co. Regional BanksFinance Provides banking and wealth management services | Corporate Officer/Principal | 01.05.2011 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops drug candidates for oncology and rare disease indications | Health Technology |
Boston Private Bank & Trust Co.
Boston Private Bank & Trust Co. Regional BanksFinance Provides banking and wealth management services | Finance |
Bates College
Bates College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Northeastern University
Northeastern University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Synlogic, Inc.
Synlogic, Inc. BiotechnologyHealth Technology Develops biopharmaceuticals | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen